# US 2003/0073637 A1 · Method for stimulating connective tissue growth or wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073637 A1
- Document ID: US20030073637A1
- Status: Published application
- Kind: A1
- Application number: 10/260,539
- Filed: 2002-10-01
- Published: 2003-04-17
- Earliest claimed: 1998-11-10
- Assignees: Ludwig Institute for Cancer Research; Licentia Ltd.
- Inventors: Marko Uutela; Ulf Eriksson; Kari Alitalo
- Web page: https://patentgrep.com/patent/US20030073637A1

## CPC

- C07K 14/49: Platelet-derived growth factor [PDGF]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides.

## Claims

### Claim 1

A method for stimulating growth of a connective tissue or healing a wound in a mammal, which method comprises administering to the mammal in need thereof an effective connective tissue growth-stimulating or wound-healing amount of a polypeptide comprising an amino acid sequence of SEQ ID NO: 25.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO: 10.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the polypeptide comprises an amino acid sequence that is at least 95% homologous with a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the mammal is human.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the polypeptide is administered in an amount ranging from about 0.1 μg/kg to about 1,000 μg/kg body weight per dose.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the polypeptide is administered in a composition comprising the polypeptide and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the polypeptide is delivered to the mammal by an expression vector expressing the polypeptide.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the expression vector comprises a tissue-specific promoter operatively linked to a polynucleotide encoding the polypeptide.

### Claim 10 (depends on 9)

A method according to claim 9, wherein the tissue-specific promoter is specific for a tissue associated with the wound or for the connective tissue.

### Claim 11 (depends on 8)

A method according to claim 8, wherein the expression vector is delivered in a cell comprising the expression vector.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the cell is a cell derived from the mammal in need thereof.

### Claim 13 (depends on 11)

A method according to claim 11, wherein the cell is a cell derived from a mammal other than the mammal in need thereof.

### Claim 14 (depends on 11)

A method according to claim 11, wherein the mammal is a transgenic mammal comprising the cell comprising the expression vector expressing the polypeptide.

### Claim 15

A pharmaceutical composition for treating a wound, or for promoting growth of a connective tissue, the composition comprising:
(a) an effective amount for stimulating connective tissue growth or wound-healing of a polypeptide comprising an amino acid sequence of SEQ ID NO:25, and
(b) a pharmaceutically acceptable carrier for delivering the polypeptide to the connective tissue or wound.

### Claim 16 (depends on 15)

A pharmaceutical composition according to claim 15, wherein the carrier is a powder, an emulsion, a cream, a lotion, an ointment, a gel, a liniment, a salve, a liposomal suspension, or an immobilizing matrix.

### Claim 17

A method for stimulating growth of a connective tissue or healing a wound in a mammal, which method comprises administering to the mammal in need thereof an effective connective tissue growth-stimulating or wound-healing amount of a polynucleotide coding for a polypeptide comprising an amino acid sequence of SEQ ID NO: 25.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:10.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the polypeptide comprises an amino acid sequence that is at least 95% homologous with a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

### Claim 21 (depends on 17)

A method according to claim 17, wherein the mammal is human.

### Claim 22 (depends on 17)

A method according to claim 17, wherein the polynucleotide is administered in a composition comprising the polynucleotide and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 17)

A method according to claim 17, wherein the polynucleotide is an expression vector expressing the polypeptide.

### Claim 24 (depends on 23)

A method according to claim 23, wherein the expression vector comprises a tissue-specific promoter operatively linked to a polynucleotide encoding the polypeptide.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the tissue-specific promoter is specific for a tissue associated with the wound or for the connective tissue.

### Claim 26 (depends on 16)

A method according to claim 16, wherein the polynucleotide is a plasmid.

### Claim 27 (depends on 16)

A method according to claim 16, wherein the polynucleotide is a viral vector.

### Claim 28 (depends on 27)

A method according to claim 27, wherein the viral vector is selected from the group consisting of a retrovirus vector, an adenovirus vector, an adeno-associated virus vector, a vaccinia virus vector, a herpes simplex virus vector, and a chimeric viral vector.

### Claim 29 (depends on 17)

A method according to claim 17, wherein the polynucleotide is administered to the mammal in need thereof in association with liposomes.

### Claim 30 (depends on 23)

A method according to claim 23, wherein the vector replicates specifically in a tissue associated with the wound or in the connective tissue.

### Claim 31

A pharmaceutical composition for treating a wound, or for promoting growth of a connective tissue, the composition comprising:
(a) an effective amount for stimulating connective tissue growth or wound-healing of a polypeptide encoding a polypeptide comprising an amino acid sequence of SEQ ID NO:25, and
(b) a pharmaceutically acceptable carrier for delivering the polynucleotide to the connective tissue or wound.

### Claim 32 (depends on 31)

A pharmaceutical composition according to claim 31, wherein the carrier is a powder, an emulsion, a cream, a lotion, an ointment, a gel, a liniment, a salve, or a liposomal suspension.
